Mural Oncology

Executive Summary

Mural Oncology is a clinical-stage immuno-oncology company founded in 2023 and headquartered in Waltham, Massachusetts. The company is pioneering novel, engineered cytokine therapies designed to harness the immune system to treat cancer, aiming to overcome historical limitations of cytokine therapies such as severe toxicity and limited efficacy. By leveraging protein engineering to create targeted and potent cytokine variants, Mural seeks to unlock the full therapeutic potential of cytokines while improving safety profiles. As a young biotech with a focused pipeline, Mural represents an early-stage investment opportunity in the immuno-oncology space, with its success hinging on clinical validation of its platform. The company's approach addresses a well-recognized challenge in oncology, positioning it as a potential player in the next wave of cancer immunotherapies. However, given its early clinical stage and lack of publicly disclosed pipeline details, conviction is tempered by the inherent risks of drug development and the competitive landscape of cytokine engineering.

Upcoming Catalysts (preview)

• Q3 2026Initial Phase 1/2 clinical trial data for lead cytokine program40% success
• Q2 2026Regulatory filings (IND) for a second pipeline candidate70% success
• Q4 2026Strategic partnership or licensing deal for platform technology30% success